CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 35 enrolled
Drug / intervention
PA21drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01850641
NCT01850641Phase 3Completed
CompareCT.gov

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Kissei Pharmaceutical Co., Ltd.·interventional·Posted May 9, 2013·Updated Oct 9, 2018

In Brief

A Phase 3 clinical trial evaluating PA21 for Hemodialysis and Hyperphosphatemia. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemodialysis, Hyperphosphatemia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 9, 2013
Enrollment StartApr 29, 2013
Primary CompletionDec 1, 2013
Study CompletionDec 3, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.1 years ago

Interventions

PA21drug